First clinical trial of purified, irradiated malaria sporozoites in humans

Daubenberger, C. A.. (2012) First clinical trial of purified, irradiated malaria sporozoites in humans. Expert review of vaccines, Vol. 11, H. 1. pp. 31-33.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6094178

Downloads: Statistics Overview


Evaluation of: Epstein JE, Tewari K, Lyke KE et al. Live attenuated malaria vaccine designed to protect through hepatic CD8 T cell immunity. Science 334(6055), 475-480 (2011). Purified, irradiated, metabolically active sporozoites of Plasmodium falciparum (PfSPZ) have been administered to 80 volunteers through subcutaneous or intradermal routes. This PfSPZ vaccine has been shown to be safe but of low immunogenicity and hence protective efficacy as shown after challenge with infected mosquitoes. Intravenous delivery of PfSPZ in nonhuman primates induced memory CD8(+) and CD4(+) T cells specific for PfSPZ that reside in the liver. Further studies using PfSPZ and the intravenous route in humans are warranted to fully explore the potential of purified, attenuated sporozoites for malaria vaccine development
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology (MPI) > Clinical Immunology (Daubenberger)
UniBasel Contributors:Daubenberger, Claudia
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Expert Reviews
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:19 Jul 2013 07:43
Deposited On:19 Jul 2013 07:39

Repository Staff Only: item control page